Following mobilising chemotherapy and myeloid growth factors, some heavily pretreated patients do not mobilise adequate numbers of peripheral blood progenitor cells (PBPC). It would be clinically useful to identify such patients in advance. A recent scoring system based on previous therapy may be useful in predicting CD34-positive cell yield. In this study we validated this scoring system on an independent group of 99 patients undergoing 103 harvesting episodes. In 61 patients mobilised with cyclophosphamide 1.5 g/m 2 and G-CSF, those with treatment scores less than 21 yielded significantly more CD34-positive cells than patients with scores greater than 63 (P = 0.0012). Previous treatment with melphalan or carmustine was associated with a significantly lower yield of CD34-positive cells (P = 0.0001). No relationship was seen between the time from previous chemoradiotherapy and harvest outcome. Patients with treatment scores less than 21 required a shorter duration of G-CSF therapy (P = 0.05). Similar findings were seen in 42 further mobilisation cycles undertaken with alternative mobilisation schedules. The present data suggest that a score summarising previous treatment can be used to predict CD34 yields, and could be of clinical use to identify poor PBPC mobilisers in advance.
fore be of considerable practical and financial use to identify poor PBPC mobilisers in advance.
The number of cycles and duration of previous chemotherapy, the interval between previous chemotherapy and mobilisation, and exposure to stem cell toxic drugs such as melphalan and nitrosoureas have all been correlated with PBPC yield (reviewed in Ref. 3) . It is, however, not currently possible to summarise previous treatment to predict which patients may be better served by alternative harvesting strategies. Recently, a score derived from previous chemoradiotherapy has been shown to predict progenitor cell yield. 4 Each chemotherapy agent is assigned an arbitrary toxicity factor based on its mode of action and available in vitro data. This factor is added to the score for each treatment cycle containing the drug. Melphalan and the nitrosoureas carry the highest toxicity factor of 4.
If the predictive value of this scoring system was to be confirmed on an independent group of patients undergoing PBPC mobilisation, it would validate its clinical usefulness in optimising PBPC harvesting resources. We have therefore examined its use to predict PBPC yield on 99 patients undergoing PBPC mobilisation at our centre.
Patients and methods
A total of 99 patients underwent 103 PBPC mobilisation cycles at our centre until December 1997. Treatment details of each patient were summarised as follows.
(1) Treatment score was evaluated as given in detail by Drake et al, 4 except that we have, in addition, arbitrarily allocated a score of 2 for ifosfamide per treatment cycle. Briefly, chemotherapy drugs are assigned a toxicity factor as follows: 0: prednisolone, dexamethasone; 1: vincristine, vinblastine, bleomycin, alpha interferon; 2: cyclophosphamide, anthracyclines, cisplatin, etoposide, ifosfamide; 3: chlorambucil, procarbazine; 4: melphalan, carmustine, mechlorethamine, lomustine. The number of courses of each drug received was multiplied by its toxicity factor, and the score for each drug administered was summed to yield an overall treatment score. An additional 2 points were added if mediastinal radiotherapy was administered. Examples of applying this to commonly used chemotherapy schedules are given in Drake et al. 4 The total number of treatment courses and cycles were not analysed separately, as these were heavily correlated with the treatment score (Pearson correlation coefficient 0.656 and 0.816 for mobilisation groups 1 and 2, respectively). For each patient, the following harvest outcome data were also recorded: CD34-positive cell yield; total nucleated cell yield; mononuclear cell yield; CFU-GM yield, each expressed as per kg recipient weight; number of harvests performed; duration of G-CSF therapy for PBPC mobilisation (days).
If transplanted solely with the stem cell harvest, the number of post-transplant days to achieve a blood neutrophil count of 0.5 and 1.0 × 10 9 /l, and a platelet count of 50 × 10 9 /l (first of at least 2 consecutive days in each case). No patient in this study received post-transplant myeloid growth factors.
Mobilisation Group 1
Sixty-one cases were mobilised using the same cyclophosphamide and G-CSF schedule, and were designated Mobilisation Group 1. Cyclophosphamide 1.5 g/m 2 was given on day 1, and G-CSF 5 g/kg/day commenced on day +6, continued until harvesting was completed. Harvesting commenced when the peripheral blood (PB) white blood count rose to 5 × 10 9 /l, or the PB CD34 count was in excess of 20 × 10 6 /l, whichever was the sooner. The distribution of underlying diagnoses in these patients is given in Table 1 .
Mobilisation Group 2
The remaining 42 cases were mobilised using a variety of schedules, using G-CSF alone (17 cases), cyclophosphamide/G-CSF based (12 cases), or with G-CSF given following disease-specific chemotherapy (13 cases). These schedules and underlying diagnoses are summarised in Table 1 . Patients mobilised using these schedules are designated Mobilisation Group 2.
Statistical comparison
The effect of each treatment variable on predicting harvest outcome was analysed in each treatment quartile by a nonparametric log rank (Mann-Whitney) test, using the Minitab statistical package release 8.2. Each mobilisation group was studied separately.
Results
In order to remove a possible bias due to variation in the mobilisation procedure, the effect of previous treatment was initially examined on Mobilisation Group 1. Sufficient details of previous treatment to calculate a treatment score were available on 60 of the 61 cases, and on 46 cases for the days since completing previous chemoradiotherapy.
Effect of previous treatment on harvest yield
The effect of treatment variables in predicting harvest yield is summarised in Table 2 . The yield of CD34-positive cells was greater in patients who had lower treatment scores. This achieved statistical significance when analysed above and below both the first and third quartile of treatment score, and there was a similar non-significant trend either side of the median treatment score of 42. Patients with low treatment scores (less than 21) yielded significantly more CD34-positive cells than patients with high treatment scores (greater than 63) (P = 0.0012).
No relationship was observed between treatment score and the CFU-GM yield, although patients with the lowest treatment scores tended to have a greater CFU-GM yield. Patients who had not received either melphalan or carmustine had a significantly greater yield of CD34-positive cells, and a similar non-significant trend was seen for CFU-GM yield.
No clear relationship was seen between the number of days since completing previous chemoradiotherapy and harvest outcome; patients who had been off treatment for a long time tended to have higher CFU-GM but lower CD34 yields.
Relationship between previous treatment and harvest duration/G-CSF usage
Patients with low treatment scores (less than 21) required a shorter duration of G-CSF therapy (P = 0.05). No similar effect was seen for patients at higher treatment scores. No relationship was seen between the treatment score and the number of harvests. Cases who had received melphalan and/or carmustine tended to require an additional harvest and a longer duration of G-CSF treatment than cases who had not received these agents. No relationship was seen between harvest number/G-CSF duration and the length of time since completing previous chemoradiotherapy.
Effect of previous treatment in predicting engraftment time
Seven of the 61 cases in Mobilisation Group 1 were undergoing PBPC collection as a precaution against future disease progression. Forty-six of the remaining 54 cases underwent transplantation solely with the harvested PBPC. No clear relationship between treatment score or melphalan/carmustine exposure and neutrophil engraftment time was seen. There was a trend toward longer platelet engraftment time in patients with higher treatment scores (P = 0.05), and if treated with melphalan/carmustine (P = 0.008). No relationship was seen between time since completing treatment and neutrophil or platelet engraftment time.
Effect of previous treatment in Mobilisation Group 2
The effect of treatment variables in predicting harvest yield for Mobilisation Group 2 is summarised in Treatment score and days since completion of previous chemoradiotherapy are analysed at the first quartile, median and third quartile points; previous melphalan/carmustine treatment as a dichotomous variable. For each pair, significantly different (P Ͻ 0.05 by the log rank (Mann-Whitney) test) results are indicated by the P value; NS = P Ͼ 0.05. Where no row of P values are given, all P values are Ͼ0.05.
in Mobilisation Group 2 had received greater amounts of previous therapy than Group 1 (median score 57 vs 42).
Patients with low treatment scores had higher CD34 yields, both when analysed above and below the median treatment score, and when the lowest quartile (less than 27) was compared with the highest quartile (78 or above) (P = 0.029).
Patients in the highest treatment quartile had a significantly lower yield of CFU-GM, and required more days of G- Comments as for Table 2 .
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CSF therapy and additional harvests. Previous exposure to melphalan/carmustine and the length of time since completing treatment were not clearly related to harvest outcome.
Discussion
We report that the numbers of CD34-positive cells mobilised by an identical cyclophosphamide/G-CSF regime (Group 1) is inversely related to the amount of previous treatment, as summarised by the score suggested by Drake et al. 4 Patients previously treated with melphalan and carmustine yield fewer CD34-positive cells than patients who have not received these agents. Similar findings were seen in a further 42 PBPC harvests after a variety of alternative mobilisation schedules. No clear relationship was seen between the treatment score and the number of harvests or the number of days for which G-CSF are required, both of which are directly related to the cost of PBPC mobilisation. No relationship was seen between harvest yield and the time since completion of previous therapy.
The present findings are in line with those of Drake et al, 4 and suggest that the treatment score can be used to predict CD34 yields. These data raise the question as to whether the treatment score can be used to identify poor PBPC mobilisers in advance. Of 15 patients in the highest treatment score quartile in Group 1, only four (27%) yielded more than 1 × 10 6 CD34-positive cells/kg, a dose often stated as the minimum number capable of supporting high-dose chemotherapy. This contrasts with 14 of 15 (87%) of patients with treatment scores under 21 yielding at least this dose. The present scoring system is therefore not absolute, although it may assess the probability of successful PBPC mobilisation. There is a wide variation in the numbers of PBPC mobilised in normal subjects, and this range may overlap with that in pretreated patients. 5 It is therefore possible that patients who were in the upper level of PBPC mobilisation in health may unexpectedly mobilise adequate PBPC numbers even after heavy prior therapy; conversely, those who were in the lower normal range may become poor mobilisers after comparatively light pretreatment.
It is not clear whether patients with high treatment scores may be best mobilised by higher doses of chemotherapy and/or G-CSF, or are better served by moving straight to autologous marrow transplantation. Patients who mobilise PBPC poorly are also likely to have poor quality marrow, and may also have a greater degree of marrow stromal damage. Any form of transplantation is therefore inherently more risky in poor PBPC mobilisers, and an alternative approach in such cases may be to avoid transplantation altogether. Further studies are needed to examine the optimal clinical approach in patients who mobilise PBPC poorly following conventional mobilising schedules. The present scoring system may be useful in predicting such patients in advance.
